middle.news
Cleo Diagnostics Advances FDA Submission and U.S. Reimbursement Pathway with A$6.2m Cash
9:39am on Wednesday 29th of July, 2026 AEST
•
Healthcare
Read Story
Cleo Diagnostics Advances FDA Submission and U.S. Reimbursement Pathway with A$6.2m Cash
9:39am on Wednesday 29th of July, 2026 AEST
Key Points
Entered Analytical Validation phase for FDA submission
Staged manufacturing program underway with Bio-Techne
U.S. reimbursement pathway established using CPT code 81599
Cash reserves of A$6.2 million support ongoing milestones
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cleo Diagnostics (ASX:COV)
OPEN ARTICLE